| Transaction Date | Recipient | Shares | Type | Price | Value |
|---|---|---|---|---|---|
| 11th August 2020 | Michael Thomas Heffernan | 13,071 | Open or private sale | $19.13 | $250,048.23 |
| 5th August 2020 | Steven C Gilman | 13,000 | Exercise of derivative | $10.63 | $138,190.00 |
| 5th August 2020 | Steven C Gilman | 13,000 | Open or private sale | $32.75 | $425,750.00 |
| 29th July 2020 | Steven C Gilman | 10,000 | Open or private sale | $29.70 | $297,000.00 |
| 29th July 2020 | Steven C Gilman | 10,000 | Exercise of derivative | $10.63 | $106,300.00 |
| 22nd July 2020 | Steven C Gilman | 10,000 | Grant/award etc. | $10.63 | $106,300.00 |
| 22nd July 2020 | Steven C Gilman | 10,000 | Open or private sale | $33.23 | $332,300.00 |
| 30th June 2020 | Mark J Enyedy | 5,241 | Grant/award etc. | $3.91 | $20,492.31 |
| 18th June 2020 | Scott A Canute | 3,718 | Grant/award etc. | $0.00 | |
| 16th June 2020 | Adrian Adams | 7,500 | Grant/award etc. | $0.00 |
Akebia Therapeutics
Akebia Therapeutics, Inc. is a biopharmaceutical company. The firm also involves in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat.
Ticker: AKBA
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1517022
Employees: 360
Exchange: NASDAQ
Auditor Opinion:
You must Login to see Language Changes
Disclosure Language changes
You must Login to see analysis
Red Flags
There were no Red Flags found
Fundamentals
Cash at Carrying Value: $245 M (0%)
Inventory, Net: $105 M (0%)
Assets, Current: $449 M (45%)
Property, Plant and Equipment, Net: $9 M (0%)
Other Assets, Noncurrent: $47 M (-37%)
Assets: $745 M (-3%)
Accounts Payable, Current: $29 M (-24%)
Accrued Liabilities, Current: $143 M (0%)
Liabilities, Current: $196 M (-5%)
Long-term Debt, Excluding Current Maturities: $76 M (0%)
Other Liabilities, Noncurrent: $42 M (37%)
Liabilities: $375 M (0%)
Common Stock, Value, Issued: $1 Th (0%)
Common Stock, Shares, Issued: $143 M (0%)
Additional Paid in Capital, Common Stock: $1 B (17%)
Retained Earnings (Accumulated Deficit): $1 B (29%)
Stockholders' Equity (Parent): $370 M (0%)
Liabilities and Equity: $745 M (-3%)
Revenue: $90 M (-49%)
Research and Development: $53 M (-60%)
Operating Income/Loss: $174 M (-25%)
